Cargando…

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan

Autosomal dominant polycystic kidney disease (ADPKD) is a cause of end-stage kidney disease (ESKD). The vasopressin V2-receptor antagonist tolvaptan has been shown within randomized clinical trials to slow down decline of kidney function in patients with ADPKD at risk of rapid progression. We perfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gkekas, Eleftherios, Tang, Tsz Yau Tiffany, Green, Alan, Davidson, Han, Fraser, Rachel, Sayer, John A., Srivastava, Shalabh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Nephrology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479563/ https://www.ncbi.nlm.nih.gov/pubmed/37674994 http://dx.doi.org/10.3389/fneph.2022.984165

Ejemplares similares

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis
por: Lu, Jingkui, et al.
Publicado: (2022)

Plant-derived compounds for treating autosomal dominant polycystic kidney disease
por: Zhang, Jieting, et al.
Publicado: (2023)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
por: Sans-Atxer, Laia, et al.
Publicado: (2013)

Umbilical hernia in autosomal dominant polycystic kidney disease
por: Hattori, Yoshinari, et al.
Publicado: (2014)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Cellular abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) fibroblasts
por: Moyes, S, et al.
Publicado: (2012)

Echocardiographic Abnormalities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients
por: Pfeferman, Mariana Becker, et al.
Publicado: (2022)

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
por: Pellegrino, Angela Maria, et al.
Publicado: (2019)

Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017)

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021)

Informatics-guided drug repurposing for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Kiseleva, Anna A., et al.
Publicado: (2020)

Systems biology approaches toward autosomal dominant polycystic kidney disease (ADPKD)
por: Rahimmanesh, Ilnaz, et al.
Publicado: (2020)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Sturge–Weber syndrome coexisting with autosomal dominant polycystic kidney disease
por: Niemczyk, Mariusz, et al.
Publicado: (2012)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
por: Bennett, Hayley, et al.
Publicado: (2019)

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model
por: McEwan, Phil, et al.
Publicado: (2018)

Large Retroperitoneal Haemorrhage Following Cyst Rupture in a Patient with Autosomal Dominant Polycystic Kidney Disease
por: Mabillard, Holly, et al.
Publicado: (2017)

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
por: Kim, Ha Yeon, et al.
Publicado: (2018)

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
por: Anderegg, Manuel A., et al.
Publicado: (2020)

Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
por: Jankowska, Magdalena, et al.
Publicado: (2015)

Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease
por: Blanchette, Christopher M., et al.
Publicado: (2014)

Twenty-Year Survival of Kidney Transplant From a Deceased Donor With Autosomal Dominant Polycystic Kidney Disease
por: Issa, Naim, et al.
Publicado: (2021)

Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) During Pregnancy: Risks and Challenges
por: McBride, Lucy, et al.
Publicado: (2020)

Clinical practice guideline monitoring children and young people with, or at risk of developing autosomal dominant polycystic kidney disease (ADPKD)
por: Dudley, Jan, et al.
Publicado: (2019)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
por: Sans-Atxer, Laia, et al.
Publicado: (2018)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
por: Kunizawa, Kyohei, et al.
Publicado: (2018)

Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Iijima, Hiroko, et al.
Publicado: (2022)

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2023)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
por: Kim, Yaerim, et al.
Publicado: (2023)

Renal Transcatheter Arterial Embolization for ADPKD
por: Oda, Yasuhiro, et al.
Publicado: (2020)

Recurrent Cholangitis in a Patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Caroli's Disease
por: Hasegawa, Eiko, et al.
Publicado: (2016)

Association of Vitamin D Levels With Kidney Volume in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Vendramini, Larissa Collis, et al.
Publicado: (2019)

Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
por: Zubidat, Dalia, et al.
Publicado: (2023)

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants
por: Harris, Tess, et al.
Publicado: (2018)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vsfv3vbdebg17o9u2g94hqea11